NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
NeuroSense Therapeutics (NASDAQ: NRSN), a late-clinical stage biotech company focused on neurodegenerative diseases, has secured a $500,000 private placement from a single investor. The company will issue 333,334 ordinary shares at $1.50 per share, representing a significant 40% premium to the September 3, 2025 closing price.
The financing, expected to close on September 8, 2025, will provide working capital and serve as a bridge to upcoming milestones. CEO Alon Ben-Noon highlighted this as their third premium-to-market financing, emphasizing minimal shareholder dilution while strengthening the company's balance sheet.
NeuroSense Therapeutics (NASDAQ: NRSN), una biotech in fase clinica avanzata specializzata nelle malattie neurodegenerative, ha ottenuto un placement privato da 500.000 $ da un unico investitore. La società emetterà 333.334 azioni ordinarie a 1,50 $ per azione, corrispondenti a un significativo premio del 40% rispetto al prezzo di chiusura del 3 settembre 2025.
Il finanziamento, che dovrebbe concludersi l’8 settembre 2025, fornirà capitale di esercizio e fungerà da ponte verso i prossimi traguardi. Il CEO Alon Ben-Noon ha sottolineato che si tratta del terzo finanziamento effettuato a premio rispetto al mercato, evidenziando una diluizione minima per gli azionisti e un rafforzamento del bilancio aziendale.
NeuroSense Therapeutics (NASDAQ: NRSN), una compañía biotecnológica en fase clínica avanzada centrada en enfermedades neurodegenerativas, ha asegurado una colocación privada de 500.000 $ por parte de un único inversor. La empresa emitirá 333.334 acciones ordinarias a 1,50 $ por acción, lo que representa una importante prima del 40% respecto al precio de cierre del 3 de septiembre de 2025.
La financiación, que se espera cerrar el 8 de septiembre de 2025, aportará capital de trabajo y servirá como puente hasta próximos hitos. El CEO Alon Ben-Noon destacó que es su tercer financiamiento por encima del mercado, poniendo énfasis en la dilución mínima de los accionistas y en el fortalecimiento del balance de la compañía.
NeuroSense Therapeutics (NASDAQ: NRSN), 신경퇴행성 질환에 주력하는 후기 임상 단계의 바이오텍 기업이 단일 투자자로부터 50만 달러 규모의 사모 배정을 확보했습니다. 회사는 주당 1.50달러에 보통주 333,334주를 발행할 예정이며, 이는 2025년 9월 3일 종가 대비 40%의 프리미엄에 해당합니다.
이번 자금 조달은 2025년 9월 8일에 마감될 예정이며, 운영자금 확보와 향후 이정표까지의 브리지 역할을 할 것입니다. CEO 알론 벤눈(Alon Ben-Noon)은 이번이 시장 대비 프리미엄으로 진행된 세 번째 자금조달이라며 주주 희석이 최소화되면서 재무구조를 강화했다고 강조했습니다.
NeuroSense Therapeutics (NASDAQ: NRSN), une société biotechnologique en phase clinique avancée spécialisée dans les maladies neurodégénératives, a obtenu un placement privé de 500 000 $ auprès d’un seul investisseur. La société émettra 333 334 actions ordinaires à 1,50 $ par action, soit une prime de 40 % par rapport au cours de clôture du 3 septembre 2025.
Le financement, qui devrait se finaliser le 8 septembre 2025, fournira des fonds de roulement et servira de pont vers les prochains jalons. Le PDG Alon Ben-Noon a souligné qu’il s’agit du troisième financement réalisé au-dessus du marché, mettant en avant une dilution minimale des actionnaires et un renforcement du bilan de la société.
NeuroSense Therapeutics (NASDAQ: NRSN), ein Biotech-Unternehmen in späten klinischen Phasen mit Schwerpunkt auf neurodegenerativen Erkrankungen, hat eine Private Placement über 500.000 $ von einem einzigen Investor erhalten. Das Unternehmen wird 333.334 Stammaktien zu je 1,50 $ ausgeben, was einem deutlichen Aufschlag von 40% zum Schlusskurs vom 3. September 2025 entspricht.
Die Finanzierung, die voraussichtlich am 8. September 2025 abgeschlossen wird, soll Betriebskapital bereitstellen und als Brücke zu bevorstehenden Meilensteinen dienen. CEO Alon Ben-Noon betonte, dass dies die dritte Finanzierung über dem Marktpreis sei, mit minimaler Verwässerung für die Aktionäre und einer Stärkung der Bilanz.
- Shares priced at 40% premium to market, indicating investor confidence
- Third consecutive financing secured at above-market pricing
- Minimal shareholder dilution due to premium pricing
- Strategic bridge financing to support upcoming milestones
- Small financing amount of only $500,000 suggests limited runway extension
- Need for bridge financing may indicate cash constraints
- Reliance on private placements for funding could signal limited financing options
Insights
NeuroSense secured $500K financing at 40% premium, providing bridge capital while minimizing shareholder dilution as company approaches key milestones.
NeuroSense's
The company has strategically limited this raise to a single investor and kept the size modest, characterizing it as a "short-term bridge" to upcoming milestones. This approach suggests management is balancing immediate capital needs while preserving shareholder value by minimizing dilution – issuing just 333,334 new shares. The fact this represents their third premium-priced private placement establishes a pattern of investor confidence.
For a late-stage clinical biotech, cash position is critical. This infusion, while relatively small, extends their operational runway as they approach what management describes as "key upcoming milestones" – likely clinical data readouts or regulatory decisions for their neurodegenerative disease pipeline. The deliberate positioning of this as interim financing suggests management anticipates more significant funding events following positive milestone achievements, when they could potentially raise capital at more favorable terms.
Financing at
Under the terms of the agreement, NeuroSense will issue 333,334 ordinary shares at a purchase price of
Proceeds from the financing are expected to be used for general corporate purposes and working capital.
Alon Ben-Noon, CEO of NeuroSense, commented: "This ordinary share only investment serves as a short-term bridge as we continue to advance our activities and prepare for our next stage of growth. This is our third financing which is with private investors at a premium to market. This enables us to strengthen our balance sheet as the Company advances toward key upcoming milestones, while minimizing dilution for our shareholders."
The offering is being made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and/or Regulation D thereunder. The securities offered and sold in this transaction have not been registered under the Securities Act and may not be offered or sold in
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.
Forward-Looking Statements
This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the offering, including as to the consummation of the offering described above, the expected gross proceeds from the offering, the intended use of proceeds and the timing of the receipt of proceeds of the offering. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk that the offering as described above will not consummate or will be delayed, the risk of a delay in submission by the Company of its regulatory dossier, that regulatory approvals for PrimeC will be delayed or not obtained in
Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-announces-500-000-private-placement-at-premium-to-market-price-302546560.html
SOURCE NeuroSense
FAQ
What is the size and price of NeuroSense (NRSN) September 2025 private placement?
When will NRSN's private placement close?
How will NeuroSense use the proceeds from the $500,000 private placement?
What is significant about NRSN's private placement pricing?
Who are the investors in NRSN's September 2025 private placement?
